Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC

NCT03813836 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

University College, London

Collaborators

[object Object]